Fennopharma

Fennopharma is a Finnish specialty pharmaceutical company that focuses on the development, registration, and marketing of value-added medicines and niche products. The company's primary expertise lies in reformulating established active pharmaceutical ingredients to create improved therapeutic options, particularly in the fields of pain management and the central nervous system. Its lead commercial product, Fennofent, is a fentanyl buccal tablet indicated for the treatment of breakthrough cancer pain. In November 2021, Fennopharma was acquired by Karo Healthcare (formerly Karo Pharma), a Swedish consumer healthcare company, to expand its portfolio of prescription and over-the-counter brands in the Nordic region.